Last reviewed · How we verify
NCT03817840
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushing's Disease
trial testing Treatment of Cushing's in Cushing's Syndrome in 8 participants. Completed in 1 July 2021.
1 July 2021
Quick facts
| Lead sponsor | Columbia University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 8 |
| Start date | 16 July 2018 |
| Primary completion | 1 July 2021 |
| Estimated completion | 1 July 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Treatment of Cushing's
Conditions studied
- Cushing's Syndrome — all drugs for Cushing's Syndrome →
Sponsor
Columbia University
Who can join
Adults 18 to 70, any sex, with Cushing's Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushing's disease. The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them. The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushing's syndrome, either from taking steroid medications or from tumors, impact body fat and metabolism by turning off brown fat, which is a type of fat that increases one's metabolism.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03817840
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cushing's Syndrome
Currently open trials in the same condition.
- NCT02019706 — Prospective Evaluation of 68Ga-DOTATATE PET/CT, Octreotide and F-DOPA PET Imaging in Ectopic Cushing Syndrome · Phase 2 · recruiting
Other Columbia University trials
Trials by the same sponsor.
- NCT06558422 — Human Models of Selective Insulin Resistance: Pancreatic Clamp · Phase 1 · not yet recruiting
- NCT07264582 — HIV/STI/HCV Testing and Overdose Prevention Among Survivors of Sex Trafficking · NA · not yet recruiting
- NCT05992415 — Know Your Pressures NYC · NA · not yet recruiting
- NCT05645211 — The AgRP and GH/IGF-1 Axis in Children · not yet recruiting
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03817840 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Columbia University
- Last refreshed: 4 June 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03817840.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing